Novo Seeds

During 2021, Seed Investments portfolio companies raised a record DKK 3 6 billion (USD 550 million) from international VCs and led three of the largest Series A financings in Europe

Through our hands-on approach, we ensure that promising projects and startup companies have the optimal conditions for success

Acesion Pharma develops new treatments for the acute cardioversion of artrial fibrillation

Galecto focuses on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases

Reapplix develops a device that produces a fully autologous dressing for wound healing

Avilex Pharma develops dimeric peptides that target PSD95 for the treatment of neuropathic pain

IO Biotech is a clinical stage biotech company developing distruptive immune therapies for immunological treatment of cancer

Inthera Bioscience is a Swiss biotech company targeting HPV+ head and neck cancer (HNSCO) and/or HPV+ genitourinary cancer as initial indication(s)

Biosyntia is a biotech startup within synthetic biology and metabolic engineering Biosyntia develops biocatalysts at an unprecedented speed and efficiency by employing a patent pending high-throughput screening technology

NMD Pharma is developing novel treatments for Neuromuscular diseases such as Myasthenia gravis and ALS The company is in preclinical development

CorWave is a French medtech company, developing a new generation of LVADs (Left Ventricle Assist Device)

Heparegenix GmbH is a German company developing a new treatment to promote liver regeneration

AMRA is a healthcare IT start-up The company is developing an automated image analysis platform for a full body MRI scan The platform will be able to quantify fat and muscle volumes across the body

The company is developing a new therapeutic protein for the treatment of neuropathic pain

AFYX Therapeutics is changing the way mucosal diseases are treated We are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options

The team has developed an expertise around the role of GIP (Gastric inhibitory polypeptide) in diabetes and obesity ANTAG is based at the University of Copenhagen

NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases

Developing molecules that uniquely modulate the synaptic vesicle protein SV2A

Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response

• 2000+ projects and companies reviewed since 2007

projects and companies reviewed since 2007

Seed Investments is comprised of a team of passionate investment professionals, dedicated to working with scientists and entrepreneurs to build biotech companies in the Nordics

The Seed Investments team is based at our headquarters in Copenhagen, Denmark